HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions

HER2-positive Breast CancerHER2+ Breast Cancer

Interventions

DRUG

Carvedilol

6.25 mg with food

DRUG

Empagliflozin

10 mg in the morning with or without food

Trial Locations (1)

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER